Craig T. Fredrickson

NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA.